Analysts expect Palisade Bio, Inc. to report revenue of 0.00 for Q4 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | ||||||||||||
| High Estimate | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||
| Low Estimate | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||
| Consensus Estimate | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Palisade Bio, Inc. to report earnings per share of -0.05 for Q2 26, against a range of -0.05 to -0.05. The most recent reported quarter, Q1 26, came in at -0.05, a 25.0% miss against the -0.04 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -3.32 | -2.32 | -1.54 | -0.47 | -0.58 | -0.38 | -0.04 | -0.05 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -2.57 | -3.26 | -1.77 | -0.66 | -0.51 | -0.26 | -0.04 | -0.04 | -0.05 | -0.05 | -0.07 | -0.05 | 0.30 | 0.51 | 0.44 | -0.42 | |||||||||||
| Low Estimate | -3.03 | -3.66 | -1.93 | -0.80 | -0.63 | -0.28 | -0.04 | -0.04 | -0.05 | -0.07 | -0.07 | -0.05 | 0.26 | 0.45 | 0.40 | -0.46 | |||||||||||
| Consensus Estimate | -2.80 | -3.46 | -1.85 | -0.73 | -0.57 | -0.27 | -0.04 | -0.04 | -0.05 | -0.06 | -0.07 | -0.05 | 0.28 | 0.48 | 0.42 | -0.44 |